

1 **Supplemental information**

2

3 **Supplementary Material/Subjects and Methods**

4 **1. Clinical study**

5 **1.1. Participants**

6 This study is part of an ongoing longitudinal study devoted to exploring the remission process
7 in AN, registered under clinical trial N° NCT04560517. Our protocol has been described in our
8 previous related publication¹. Inclusion criteria were: female patients between 18 and 60 years
9 old, with DSM-5 criteria of anorexia nervosa (AN). Thirty-two patients were included in a
10 department specialized in eating disorders (CMME, GHU Paris Psychiatrie et Neurosciences).
11 All participants included had three visits i/ the first visit (V1), in an undernourished state,
12 performed in the first week after admission of inpatients, ii/ the second visit (V2) took place
13 after four months of intensive care and before hospital discharge when participants reach a
14 target body mass index (BMI>19 kg/m²) therefore being considered as in a refed state, iii/ the
15 third visit (V3) took place six months after discharge with an evaluation of the remission status
16 (still present *versus* lost). Stable remission status consisted of a maintained weight restoration
17 6 months after discharge (BMI>18.5 kg/m²) whereas early weight loss characterized unstable
18 remission. The present study explored only behavioral and metabolic markers from the visit
19 after weight restoration as well as the remission status. The visit consisted of a clinical
20 evaluation which included the assessment of weight, BMI, a blood sample for metabolic
21 explorations, and a psychiatric evaluation with assessment of AN subtype (Restrictive “AN-R”,
22 or Binge Purge “BP”) and eating disorder symptoms with Eating Disorder Inventory, EDI-2².
23 The French version of the EDI-2 was used to assess symptoms severity and different clinical
24 dimensions of AN: drive for thinness, bulimia, body dissatisfaction, ineffectiveness,
25 perfectionism, interpersonal distrust, interoceptive awareness, maturity feat, ascetism, impulse
26 regulation and social insecurity. The impulse regulation subscale was added to the later EDI-
27 2 version to reflect the ability to regulate impulsive behavior, especially the binge behavior.

28 **1.2. Blood collection**

29 Blood was collected at each visit after an overnight fast on Vacutainer tubes treated with EDTA
30 and Aprotinin (Cat#454261, Greiner Bio One SAS, Courtaboeuf, France). After collection,
31 blood was kept at 4°C before centrifugation within 2h (1000xg for 10 min at 4°C). Plasma was
32 aliquoted and one aliquot was immediately acidified with HCl (final concentration of 0.1N).
33 Samples were stored at -80°C at Centre de Ressources Biologiques (CRB) of GHU Paris
34 Psychiatrie et Neurosciences and assayed within 6 months.

35 **2. Preclinical study**

36 **2.1. Food Restriction and refeeding protocol**

37 To evaluate the impact of chronic food restriction on cognitive impulsivity in rodents, we used
38 a progressive food restriction procedure adapted from the Food Restriction and Wheel
39 protocol³. Animals were acclimatized in the facilities for a week. Then, mice and their food
40 intake were weighted daily. Baseline food intake per cage was calculated as a mean of daily
41 food intake on the past 5 days and considered as *ad libitum* food intake. Body weight on that
42 day was also considered as *ad libitum* body weight.

43 Two experiments were performed (Figure 1A). For both experiments, mice were randomized
44 in different groups. There were two groups of 8 animals in **experiment 1**: control group (CT)
45 and food restricted group (FR); and three groups of 10-12 animals in **experiment 2**: control
46 group, food restricted group and food restricted + refeeding group (FR + R). Animals were
47 placed under mild food restriction to enhance motivation for reward and to allow the learning
48 of the DDT task with a target at 85-90% of the *ad libitum* body weight. Food was delivered daily
49 around 5:00 PM as individual pellets of similar weight to avoid competition between mice. The
50 mice of the control group were submitted to the mild food restriction until the end of the protocol.
51 Mice of the FR group were exposed to a 50% calorie restriction of their *ad libitum* food intake
52 for 15 days. For the **experiment 2**, mice of the FR+R group were refed with *ad libitum* access
53 to the food during 10 days after the food restriction described above.

54 Mice were housed two per cage to limit stress for behavioral tests. All animals were exposed
55 to a mild food restriction during 25 to 35 days of training to the delay discounting task (DDT)
56 and the first test (DDT1) was used as a baseline evaluation of the individual discounting. Then,
57 the FR group was submitted to 15 days of food restriction as previously described during which
58 all animals had a session of magnitude discrimination training every three days to maintain
59 task acquisition. After the 15 days, CT and FR group performed a second DDT test (DDT2) to
60 assess the impact of food restriction on cognitive impulsivity. Finally, animals of the CT and
61 FR groups have performed a reversal learning test. All animals were sacrificed at the end of
62 the protocol to collect brain and blood samples.

63 **2.2. Delay discounting task for rodents**

64 **2.2.1. Experiments**

65 **Experiment 1.** Mice were housed two per cage to limit stress for behavioral tests. All animals
66 were exposed to a mild food restriction until the first test (DDT1) that was used as a baseline
67 evaluation of the individual discounting. After the 15-day food restriction, CT and FR group
68 performed a second DDT test (DDT2) to assess the impact of food restriction on cognitive
69 impulsivity. Finally, animals of the CT and FR groups have performed a reversal learning test.
70 All animals were sacrificed at the end of the protocol to collect brain and blood samples.

71 **Experiment 2.** Animals were housed 4-5 per cage. The procedure was similar than experiment
72 1, After baseline evaluation in DDT1 mice of the FR and FR+R groups were submitted first to
73 food restriction as described above and the three groups were tested on DDT2, the mice of
74 the FR group were then sacrificed to collect brain samples. Finally, mice of the CT and FR+R
75 group were tested a third time (DDT3) after 10 days of refeeding (see previous section). All
76 animals of CT and FR+R groups were sacrificed for brain and blood samples at the end of the
77 protocol.

78 **2.2.2. Apparatus**

79 Behavioral explorations took place in 8 operant chambers (MedAssociates® MED-008-CT-B3)
80 on weekdays between 09:00 AM and 12:00 AM in a quiet room. Each chamber is protected
81 from ambient noise and light being housed in an individual cabinet that is closed during the
82 session. The operant wall contains three head entry detectors: two side holes and a central
83 magazine where food is delivered in a food cup (Figure 1B). Target holes and food delivery
84 are indicated with individual light cues. Liquid reward is delivered in the food cup through
85 silicone tubing connected to a 10 mL syringe adapted on MedAssociates syringe pumps (motor
86 speed = 3.33 rpm). We used a liquid reward mix of 1:1 strawberry flavored milk (commercially
87 available) and strawberry flavored water added with natural sweetener (natural strawberry
88 flavor 4g/l + Rebaudioside A 1,75g/l). This mix allowed a highly hedonic reward with limited
89 caloric intake compared to pure strawberry flavored milk. The caloric intake was 285 kcal/L.
90 Water was withdrawn from homecages 2 hours prior to the test to trigger motivation for liquid
91 rewards. The DDT protocol has been designed thanks to David Fuller (engineer at K-Limbic)
92 with the K-Limbic Software®.

93 **2.2.3. Operant conditioning paradigm**

94 **Delay-discounting task.** We designed a delay-discounting task adapted from the literature
95 (Mitchell, 2014). The animals performed one session of 40 minutes every day. During a
96 session, the animal had to perform several trials involving a side hole choice and consumption
97 of the corresponding reward. Two trials were separated with a 10 sec inter-trail interval (ITI),
98 when all lights turned off (Figure 1C). The protocol was divided into 5 stages: 4 training stages
99 and the test (Figure 1D).

100 1- **Habituation:** on the first day of food restriction, mice were placed in the operant
101 chamber with 40 μ L of food reward dripping in the central magazine every 2 minutes to
102 limit neophobia.

103 2- **Center nose poke learning:** animals were trained to poke in the central magazine to
104 receive a reward of 40 μ L. Only pokes during the 20 sec illumination intervals were

105 reinforced. Success was determined if the animal could get 40 rewards per session on
106 two successive sessions and could access the subsequent stage.

107 3- **Side pokes learning:** animals were then trained to activate side pokes and obtain the
108 reward in the central magazine. Left and right pokes were active during 20 seconds,
109 indicated with a light cue and a head poke in one of the side holes delivered a 40 μ L
110 reward in the food cup indicated by the illumination of the central magazine for a
111 maximum of 3600 seconds before a 10 seconds ITI. This stage permitted to evaluate
112 the lateralization bias of each animal. We determined the baseline side preference
113 considered as the side with the maximum number of pokes per session. Success was
114 determined if the animal could get 40 rewards per session on two successive sessions
115 and could access the subsequent stage.

116 4- **Magnitude discrimination:** this stage was like the previous one except one side was
117 rewarded with a small (20 μ L) reward and the other with a large (60 μ L) reward. The
118 small reward side was the preferred side determined with the baseline side preference
119 to limit bias. The large reward side stayed the same until the end of testing. Magnitude
120 discrimination was determined when animals chose the large reward in more than 80%
121 of the trials per session in two successive sessions with an inter-session variance under
122 10%.

123 After training, testing consisted of a 5-day protocol. The large reward was delivered with an
124 increasing delay each day (0 sec, 5 sec, 10 sec, 20 sec, 40 sec) and the small reward remained
125 delivered immediately. Animals had to choose between a “Small Soon” reward (SS) and a
126 “Large Late” reward (LL) as represented in Figure 1C-D.

127 The following behavioral components were recorded:

128 - Completed trials: trials containing a side poke during the 20 sec active phase followed
129 by central food retrieval in the 3600 sec active phase (correct + incorrect trials).

130 - Correct trials: LL choice

131 - Incorrect trials: SS choice

132 - Omitted trial: no side poke or no central magazine poke during active phases.

133 - Perseverative pokes: side pokes during food delivery and central magazine activity.

134 - Latency to poke: latency to poke in the SS or LL side poke in the 20 sec of illumination

135 of both side-pokes.

136 **Reversal learning task.** In experiment 1, we added a reversal learning task to evaluate the
137 consequences of chronic food restriction on cognitive flexibility.

138 The day after the DDT test, animals were exposed to a simple fixed-ratio operant conditioning
139 task in which the side hole associated with the large reward was rewarded with a 40 μ L reward
140 (1 poke for 1 reward) and the opposite side was not rewarded anymore. We verified that mice
141 learned the new rules and reached the success criterion of 75% of successful trials with a poke
142 on the rewarded side for two consecutive sessions.

143 After the DDT, animals were exposed to a Fixed-ratio 1 (FR1) in the same apparatus as
144 previously. Only the LL side remained rewarded with the delivery of 40 μ L of milk. Mice
145 performed one session per day. A session lasted 40 minutes or stopped after 60 successful
146 trials. Mice has to reach a criterion of 75% of successful trials (poke in the rewarded hole) for
147 two consecutive sessions before moving to the reversal trial. For the reversal trial, the
148 rewarded hole and the non-rewarded hole were reversed.

149 **Behavioral data analyses.** Temporal discounting is calculated as the rate at which the
150 subjective value of the reward decreases with larger delays. Delay discounting was assessed
151 using the % LL/LL+SS criteria for each delay during the block session. The preference for the
152 LL option was calculated as the percentage of choice for the large option compared to the
153 number of completed trial during the session for each delay.

154 We integrated the interindividual differences on the magnitude discrimination estimated as the
155 % LL/LL+SS without delay (delay of 0 sec). We therefore calculated the percentage of
156 decrease of the preference using the preference with the delay of 0 sec as baseline. The
157 preference decrease for the delay (x) was calculated as the decrease between the preference

158 for the LL option when the delay (x) was applied versus the baseline preference for the LL
159 option when no delay was applied.

160 Each delay was associated with a preference expressed as a percentage for each animal.
161 Hyperbolic model is the most reliable criteria to interpret data from a delay discounting test ³⁵.
162 We therefore tried to apply a similar model to preclinical data to facilitate the design of
163 translational protocols that could use similar math to calculate discounting parameter. We
164 determined a discounting parameter (k_{DD}) for each animal, calculated from a hyperbolic model
165 applied to the % LL choice as a function of delay curve using the following formula:

166

$$\% \text{ LL choice} = \frac{100}{1 + k_{DD} * \text{delay (s)}}$$

167 The discounting parameter was calculated as the best-fit value in a non-linear curve fit model
168 and was determined for each animal at each DDT test session.

169 Motor impulsivity was evaluated through the number of perseverative pokes during the delay
170 and the latency to poke for the large or the small reward, expressed in seconds.

171 For the reversal learning, we calculated the percentage of correct trials as the number of
172 rewarded pokes on total number of side pokes. The number of trials increased during the
173 reversal learning task.

174 **2.4 Sample collection for metabolic explorations**

175 Brain tissue biopsies from hypothalamus, nucleus accumbens (NAc), dorsal striatum (DS) and
176 prefrontal cortex (PFC) were collected from fresh brains using a micropunch. Blood was
177 collected at sacrifice from trunk blood on an EDTA-coated tube supplemented with PHMB (p-
178 hydroxymercuribenzoic acid), a cysteine protease inhibitor, at 0.4 mM final concentration in
179 blood. Samples were kept on ice and centrifuged at 4°C (1000 g for 10 min) to collect plasma.
180 Two aliquots of plasma were prepared: one aliquot was immediately acidified with HCl (0.1N
181 final concentration) to preserve ghrelin stability then frozen on dry ice and the second aliquot

182 was frozen directly without acidification. Plasma samples were then stored at -80°C until
183 assays.

184 **2.5 RT-qPCR analyses**

185 Total RNA was extracted using Trizol reagent (Invitrogen Life Technologies, Thermo Fisher
186 Scientific, Waltham, USA) and cDNA was obtained from reverse transcription of 1 µg of total
187 RNA. A RQ1 DNase step (Promega France, Charbonnières-les-Bains) was performed on total
188 RNA before reverse transcription with High Capacity cDNA Reverse Transcription Kit (Applied
189 Biosystems, Foster City, CA, USA). Quantitative real-time PCR was performed using SYBR
190 Green technology (LightCycler® 480 SYBR Green I Master (Roche Diagnostics, Meylan,
191 France) or PowerTrack SYBR Green (Applied Biosystems, Foster City, CA, USA) on the
192 LightCycler 480 system (Roche Diagnostics, Meylan, France). Target genes were Agouti-
193 related Protein (*AgRP*), Neuropeptide Y (*NPY*), Proopiomelanocortin (*POMC*), Growth
194 Hormone Secretagogue Receptor (*GHSR*), Leptin receptor (*LepR*) as well as dopamine
195 receptors *DRD1* and *DRD2*. The comparative $\Delta\Delta Ct$ method, where Ct is the threshold cycle
196 at which amplified PCR product was detected, was used to assess the relative expression of
197 the target genes normalized to the *Ppia* transcript (housekeeping gene). All Primers sequences
198 are available upon demand.

199 **3. ELISA immunoassays**

200 Plasma concentration of acyl ghrelin (AG) was evaluated with specific enzyme-immunoassay
201 kits (Cat#A05106 for human, CA#A05117 for mouse/rat, Bertin Bioreagents, Montigny le
202 Bretonneux, France). All used samples came from acidified aliquot as acidification is known to
203 preserve ghrelin stability. External quality control of the same mice and human plasma was
204 respectively used in all assays to ensure inter-assay stability. Intra- and inter- assay
205 coefficients of variation were <9% and <16% respectively in humans, 7% and 8% in mice.
206 Plasma concentrations of LEAP2 were measured with enzyme-immunoassay kit (Cat#EK-075-
207 40, Phoenix Pharmaceuticals, Burlingame, USA). The commercial kit used here recognizes
208 both mouse and human LEAP2, i.e. LEAP2 (38-77) (Human) / LEAP2 (37-76) (Mouse) (100%

209 cross-reactivity). External quality control of the same human plasma was respectively used in
210 all assays to control inter-assay variation. Intra- and inter-assay coefficient of variation were
211 respectively <10% and <15%. Concentrations were transformed in pmol/L and the
212 Ghrelin/LEAP2 molar ratio was calculated using molar ratio.

213

214 **References**

215 **1.** Tezenas du Montcel C, Duriez P, Cao J, Lebrun N, Ramoz N, Viltart O *et al*. The role of
216 dysregulated ghrelin/LEAP-2 balance in anorexia nervosa. *iScience* 2023; 107996.

217 **2.** Garner DavidM. EDI-2: Eating Disorder Inventory-2. *Odessa Psychol Assess Ressour* 1991.

218 **3.** Méquinion M, Chauveau C, Viltart O. The use of animal models to decipher physiological
219 and neurobiological alterations of anorexia nervosa patients. *Front Endocrinol* 2015; **6**: 68.

220




Fig S1. Schematic representation of the experiments and body weight changes. A

Timeline of the experiment and representation of the three experimental groups (Designed with Biorender). **B-C** Percentage of *ad libitum* body weight during DDT tests in experiment 1 (B) and 2 (C). Mild food restriction leads to similar weight loss in DDT1 but FR mice exhibit decreased body weight compared to CT mice in DDT2. **C** Evolution of body weight in experiment 2 after food restriction for FR and FR+R groups in DDT2. Data are expressed as mean \pm sem. Within group comparisons ***p < 0.0001; Between group comparison ##p < 0.01, ###p < 0.001. CT: control, DDT: delay discounting task, FR: food restriction, FR+R: food restriction + refeeding, RM: repeated measures.





Fig S2. Description of the training stages and the DDT phases and behavioral exploration in food restricted mice in experiment 1. **A** Schematic representation of training and testing in the DDT paradigm (Designed with Biorender). **B** Devaluation coefficient (k_{DD}) based on a hyperbolic model in FR compared to CT mice. **C** Preference for the larger reward with increasing delays (5 to 40 sec) in FR compared to CT mice. **D** Motor impulsivity evaluated with the latency to poke for the LL reward in FR compared to CT mice. **E** Number of perseverative pokes in the LL side in FR compared to CT mice. **F** Number of correct trials during the reversal learning stage in FR compared to CT mice. **G** Simple linear correlation between the percentage of correct trials on day 3 of the RL task and the percentage decreased choice for the LL reward on the 40-sec delay in DDT2. Data are expressed as mean \pm sem. Within group comparison: * p <0.05. Between groups comparison: # p <0.05, ## p <0.01, ##### p <0.0001. RM: repeated measures, RL: Reversal Learning, n=7 mice per group. DDT: Delay Discounting Task, CT: Control, FR: Food Restriction, k_{DD} : Devaluation coefficient, LL: Large Late (delayed gratification).

A



B






Fig S3. Expression of hypothalamic biomarkers of the nutritional status in CT, FR and FR+R conditions and correlation matrix in FR+R conditions. **A** Expression of hypothalamic AgRP, NPY, POMC, GHSR and LepR in CT, FR and FR+R mice. **B** Correlation matrix between k_{DD} , plasma levels of LEAP2, ghrelin, ghrelin/LEAP2 ratio and gene expressions of hypothalamic genes in the FR+R group (See also Table S4 for r and p-value). Data are expressed as mean \pm sem. ***p<0.0001. AgRP: Agouti Related Protein, CT: Control, FR: Food Restriction, FR+R: Food Restriction + Refeeding, GHSR: Growth Hormone Secretagogue Receptor, k_{DD} : Devaluation coefficient, LEAP2: Liver Expressing Antimicrobial Peptide 2, LepR: Leptin receptor, NPY: Neuropeptide Y, POMC: Proopiomelanocortin.

Food Restricted + Refed (n=8)


A



B



C



D




Fig S4. Correlation between the devaluation coefficient k_{DD} and plasma levels of ghrelin, LEAP2 and ghrelin/LEAP2 ratio in FR+R conditions. A-C: Simple linear regression between the devaluation coefficient (k_{DD}) on DDT3 and plasma levels of ghrelin (A), LEAP2 (B), and ghrelin/LEAP2 molar ratio (C) in refed animals. **D** Simple linear regression between plasma levels of LEAP2 and the percentage decreased preference for the LL reward on DDT3. Data are expressed as coefficient of determination (r^2) and p-value. Dotted lines represent the 95% confidence band of the best fit line. CT: control, DDT: delay discounting task, LL: Large Late, FR: food restriction, FR+R: food restriction + refeeding, LEAP2: Liver Expressed Antimicrobial Peptide 2, k_{DD} : Coefficient of devaluation. Correlation performed with simple (A-C) or multiple (D) linear regression.

Food Restricted + Refed (n=7-8)




Fig S5. Correlation between the expression of DRD1 and DRD2 in brain structures of the cortico-striatal network in FR+R conditions. Simple linear regression in the dorsal striatum (A), nucleus accumbens (B) and prefrontal cortex (C). Data are expressed as coefficient of determination (r^2) and p-value. Dotted lines represent the 95% confidence band of the best fit line. DRD1: dopamine receptor type 1, DRD2: dopamine receptor type 2.

Descriptive statistics	All (n=30)	Stable remission (n=14)	Unstable remission (n=16)	Statistical test, p-value
Age (years)	26.41±1.62	24.71±1.52	27.72±2.63	U=120 p=0.829
Subtype (AN-R/AN-BP)	25 (78%)/7(22%)	10 (71%)/4(29%)	15 (83%)/3(17%)	χ^2 =0.653 p=0.419
BMI (kg/m ²)	20.02±0.081	20.22±0.091	19.84±0.115	U=54 p=0.014
EDI-2 score	62.430±7.640	71.14±13.30	51.59±7.834	U=93.50 p=0.321
Impulse regulation	3.067±0.717	4.429±1.217	2.000±0.725	U=80 p=0.178
Ghrelin (pmol/L)	21.35±3.80	18.43±5.55	23.90±5.29	U=79 p=0.179
LEAP2 (pmol/L)	3160±297	3195±437	2946±395	U=117 p=0.750
Ghrelin/LEAP2 molar ratio	0.007±0.001	0.006±0.001	0.008±0.001	U=114 p=0.659

Table S1. Descriptive statistics of the population of the cohort study after weight restoration. Data are expressed as mean ± SEM. Mann Whitney paired t-test and χ^2 test, p<0.05 considered significant. AN: Anorexia Nervosa, AN-R: Anorexia Nervosa Restrictive-type; AN-BP: Anorexia Nervosa_Bingeing/Purging-type, BMI: Body Mass Index, EDI-2: Eating Disorder Inventory 2, LEAP2: Liver Expressed Antimicrobial Peptide 2.

Correlation with k_{DD}	Group	Experiment 1 Food restriction	
		CT	FR
Ghrelin (pmol/L)	r	-0.642	0.576
	r^2	0.003	0.331
	p -value	0.697	0.176
LEAP2 (pmol/L)	r	-0.181	0.391
	r^2	0.413	0.153
	p -value	0.119	0.386
Ghrelin/LEAP2 molar ratio	r	0.169	0.175
	r^2	0.028	0.031
	p -value	0.718	0.708
% AL Body weight	r	-0.389	-0.343
	r^2	0.150	0.118
	p -value	0.388	0.452

Table S2. Correlations between the devaluation coefficient (k_{DD}), metabolic status plasmatic markers and body weight decrease in FR conditions. Data are expressed as Pearson's r coefficient, r^2 and p -value. AL: *Ad libitum*, CT: control, FR: food restricted, k_{DD} : devaluation coefficient, LEAP2: Liver Expressed Antimicrobial Peptide 2.

Correlation matrix	kDD		LEAP2		Ghrelin		Ghrelin/LEAP2 molar ratio		AgRP		GHSR		NPY	
	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value
kDD														
LEAP2	0.855	0.007												
Ghrelin	0.150	0.723	0.375	0.360										
Ghrelin/LEAP2	-0.647	0.083	-0.659	0.076	0.405	0.320								
AgRP	0.061	0.885	0.127	0.765	0.726	0.0415	0.320	0.439						
GHSR	0.087	0.837	-0.147	0.729	-0.171	0.686	-0.0131	0.975	-0.074	0.862				
NPY	0.024	0.955	0.111	0.794	0.751	0.032	0.348	0.398	0.939	0.001	0.067	0.875		
POMC	-0.379	0.354	-0.283	0.497	0.595	0.119	0.630	0.094	0.843	0.009	0.117	0.783	0.841	0.009

Table S3 (refering to Fig 2D). Correlation matrix between the devaluation coefficient k_{DD} and the expression of dopaminergic receptors

DRD1 and DRD2 in the DS, NAc and PFC. DS: dorsal Striatum, DRD1: Dopaminergic Receptor type 1, DRD2: Dopaminergic Receptor type 2,

k_{DD} : devaluation coefficient, LEAP2: Liver expressed Antimicrobial Peptide 2, Nac: nucleus accumbens, PFC: prefrontal cortex. Data are

expressed as Pearson's r coefficient and p-value.

Correlation matrix	kDD		LEAP2		Ghrelin		Ghrelin/LEAP2 molar ratio		DS DRD1		DS DRD2		NAc DRD1		NAc DRD2		PFC DRD1	
	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value	Pearson r	p-value
kDD																		
LEAP2	0.855	0.007																
Ghrelin	0.150	0.723	0.375	0.360														
Ghrelin/LEAP2	-0.647	0.083	-0.659	0.076	0.405	0.320												
DS DRD1	-0.602	0.114	-0.391	0.338	-0.149	0.725	0.163	0.700										
DS DRD2	-0.498	0.209	-0.178	0.673	0.465	0.245	0.430	0.289	0.722	0.043								
NAc DRD1	-0.061	0.897	0.017	0.970	-0.055	0.906	-0.231	0.617	-0.239	0.606	-0.306	0.504						
NAc DRD2	-0.435	0.281	-0.342	0.406	-0.223	0.595	0.077	0.856	-0.087	0.837	-0.306	0.460	0.829	0.021				
PFC DRD1	-0.685	0.061	-0.340	0.410	0.123	0.772	0.226	0.590	0.617	0.103	0.571	0.139	0.527	0.224	0.563	0.146		
PFC DRD2	-0.436	0.280	-0.112	0.792	0.405	0.320	0.442	0.273	0.022	0.959	0.234	0.577	0.229	0.621	0.445	0.269	0.419	0.302

Table S4 (refering to Figure S3B). Correlation matrix between k_{DD}, plasma levels of LEAP2, ghrelin, and hypothalamic gene expression.

AgRP: Agouti Related Protein, GHSR: Growth Hormone Secretagogue Receptor, k_{DD}: devaluation coefficient, LEAP2: Liver expressed

Antimicrobial Peptide 2; NPY: Neuropeptide Y, POMC: Proopiomelanocortin. Data are expressed as Pearson's r coefficient and p-value.